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A B S T R A C T
Background
Current guidance suggests that we should monitor the physical health of people with serious mental illness, and there has been a
signiﬁcant ﬁnancial investment over recent years to provide this.
Objectives
To assess the effectiveness of physical health monitoring, compared with standard care for people with serious mental illness.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (October 2009, update in October 2012), which is based on regular
searches of CINAHL, EMBASE, MEDLINE and PsycINFO.
Selection criteria
All randomised clinical trials focusing on physical health monitoring versus standard care, or comparing i) self monitoring versus
monitoring by a healthcare professional; ii) simple versus complex monitoring; iii) speciﬁc versus non-speciﬁc checks; iv) once only
versus regular checks; or v) different guidance materials.
Data collection and analysis
Initially, review authors (GT, AC, SM) independently screened the search results and identiﬁed three studies as possibly fulﬁlling the
review’s criteria. On examination, however, all three were subsequently excluded. Forty-two additional citations were identiﬁed in
October 2012 and screened by two review authors (JX and MW), 11 of which underwent full screening.
Main results
No relevant randomised trials which assess the effectiveness of physical health monitoring in people with serious mental illness have
been completed. We identiﬁed one ongoing study.
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Authors’ conclusions
There is still no evidence from randomised trials to support or refute current guidance and practice. Guidance and practice are based
on expert consensus, clinical experience and good intentions rather than high quality evidence.
P L A I N L A N G U A G E S U M M A R Y
Physical health care monitoring for people with serious mental illness
People with mental health problems often have complex and long-term difﬁculties with their physical health such as weight gain,
smoking and heart problems. They sometimes do not take care of themselves, have inactive lifestyles and may not be able to cope with
daily life or work. People with mental health problems have higher rates of diabetes, lung disease, cancer, heart problems, HIV/Aids
and other infectious diseases.
Physical health care monitoring can take a variety of forms from simple checks carried out by the person themselves to complex speciﬁc
health checks carried out by health professionals. Monitoring helps identify current health problems and also anticipate future health
problems.
In August 2006 the United Kingdom’s Department of Health issued guidance on how to provide better care for the physical health
needs of people with serious mental illness. Spearhead Trusts, the Royal College of Psychiatrists, the National Institute for Clinical
Excellence and other organisations all promoted the use of physical health care monitoring for people with mental health problems.
This review intended to ﬁnd evidence to support this guidance. The authors’ conclude that current guidance and practice on physical
health monitoring lacks a ﬁrm basis in research and there is little evidence to support this growing trend. They based their conclusions
on results from a search carried out for trials in 2012 which found no relevant randomised studies. Current monitoring is mainly based
on the agreement of experts, medical experience and good intentions. This does not mean that physical health monitoring is invalid,
wrong or not of beneﬁt to the physical health of people with severe mental illness, only that there is as yet no deﬁnite proof. Physical
health care monitoring has the potential and promise to improve quality of life and help people with mental health problems live longer,
but at this stage the information is uncertain and the research evidence unclear.
This summary has been written by a consumer, Benjamin Gray, from Rethink Mental Illness. Email: ben.gray@rethink.org
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Physical health monitoring compared to no monitoring for people with serious mental illness
Patient or population: patients with people with serious mental illness
Settings:
Intervention: physical health monitoring
Comparison: no monitoring
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No monitoring Physical health monitor-
ing
Physical health - failure
to identify a disease state
and provide appropriate
treatment
See comment See comment Not estimable 0
(0)
See comment We did not identify any
trial-based data for any
outcome.
Physical health - failure
to effectively manage a
known disease state
Quality of life: Loss of
activities of Daily Living
(ADL) skills
Adverse event - clinically
important adverse effect
Adverse event - death
Economic - increase
costs of care
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as a result of preventable
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B A C K G R O U N D
Description of the condition
The deﬁnition of severe mental illness with the widest consen-
sus is that of the National Institute of Mental Health (NIMH)
(Schinnar 1990) and is based on diagnosis, duration and disability
(NIMH 1987). People with serious mental illness have conditions
such as schizophrenia or bipolar disorder, over a protracted period
of time and resulting in erosion of functioning in day to day life. A
European survey put the total population-based annual prevalence
of serious mental illness at approximately two per 1000 (Ruggeri
2000). As a consequence of their illness, peoplewith seriousmental
illness have a signiﬁcantly reduced life expectancy for a variety of
reasons including poor self care, adverse health behaviours (smok-
ing, sedentary lifestyle) and negative effects from psychotropic
medications (weight gain, metabolic syndrome) (Robson 2007).
In schizophrenia, for example, life expectancy is reduced by around
10 years (Newman 1991). A recent publication has shown that
people with schizophrenia have a threefold increase in mortality
compared with the general population of England and Wales, and
that approximately 81% of that increase is from natural causes,
especially cardiovascular disease (Brown 2010). There is histori-
cal evidence that sufferers from serious mental illness also have
increased rates of infectious diseases (including HIV) (Cournos
2005), non-insulin dependent diabetes, respiratory disease and
cancer (Dixon 1999; Robson 2007). Despite this, evidence says
that there exists a lack of physical health monitoring in people
with serious mental illness in both the primary care (Burns 1998)
and in the secondary care setting (Paton 2004).
Description of the intervention
Physical health monitoring can take many forms, and these forms
are highly divergent and dependent on environmental and socioe-
conomic factors. In some instances monitoring is indicated for
a speciﬁc group of people because of demographic risk factors;
one such population is those suffering from serious mental illness
(Robson 2007). People with illnesses such as schizophrenia are at
greater risk for a number of conditions. This is compounded by
the fact that they are less likely to seek medical advice and more
likely to be exposed tomedicationswith potentially negative health
consequences (Weinmann 2009). People with serious mental ill-
nesses should stand to beneﬁt greatly from a programme of well
organised and regular physical health monitoring.
Monitoring differs from promotion in that its principle aim is
to obtain information which can then be acted on to treat or
prevent a physical health problem. Promotion, on the other hand,
is the provision of information and encouragement to people in
the hope that they will act to avoid deterioration of current health
or development of future health problems. The effects of physical
health promotion or advice for people with serious mental illness
is evaluated in another future review in this series: ’Physical health
advice for people with serious mental illness’.
Past reviewers have suggested that “essential routine health mon-
itoring [for people with serious mental illness] should include
weight, body mass index (BMI) and waist circumference, blood
pressure, lipid proﬁles, screening for insulin resistance and dia-
betes, dental checks and eye health checks” (Robson 2007). Phys-
ical health care monitoring could, therefore, range from the sim-
plest forms of self monitoring through to more systematised self
screening, to well regulated and guideline-directed monitoring of
health by healthcare professionals.
How the intervention might work
Information obtained from physical health monitoring is often
the catalyst for more intensive medical input, which can be ei-
ther curative, palliative or preventative. The routine employment
of simple and relatively inexpensive physical health monitoring
has the potential to identify current, and pre-empt future, health
problems. Subsequent action could improve the quality and dura-
tion of life for sufferers of serious mental illness. Additional ben-
eﬁts may include a reduction in dependence on medical services.
“There are potential savings to be made on prescribing and acute
care budgets through prevention or early detection of serious ill-
ness in these groups of service users” (DoH 2006).
Why it is important to do this review
In August 2006 the UK’s Department of Heath published a com-
missioning framework (DoH 2006) which, based on examples of
current practice (including pilot programmes and expert advice),
was intended to provide best practice guidance on the physical
health needs of people with severe mental illness. In conjunction
with this publication there has been signiﬁcant investment in 88
English Primary Care Trusts, known as ’Spearhead’ Trusts, to im-
plement the services it suggested. In addition, a raft of guidance
around physical heath monitoring in psychiatry has arisen over
recent years from organisations such as the Royal College of Psy-
chiatrists (RCPsych 2009; RCPsych 2009a), the National Insti-
tute for Clinical Excellence (NICE 2006), Maudsley Prescribing
Guidelines (Taylor 2009) and the Serious Mental Illness Physical
Health Improvement Proﬁle (White 2009). At no point do the
current commissioning framework or guidance documents refer
to evidence from randomised controlled trials or previous system-
atic reviews. This pathway of identifying a problem, consultation,
creation of guidelines and investment to implement the guidance
would appear to make good sense. We feel that at this point it
would be good to assess the available evidence on the effects of
physical health monitoring. This is one of a series of related re-
views (Table 1).
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O B J E C T I V E S
Toassess the effectiveness of physical healthmonitoring, compared
with standard care for people with severe mental illness.
A secondary objective was to compare types and techniques of
monitoring.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all relevant randomised controlled trials and eco-
nomic evaluations conducted alongside included randomised con-
trolled trials. We excluded studies such as those allocating partic-
ipants to groups by using alternate days of the week. If we had
encountered trials described in some way to suggest or imply that
the study was randomised, and where the demographic details of
each group’s participants were similar, we would have included
them and a sensitivity analysis would have been undertaken to
assess the inﬂuence of the presence or absence of these data on the
results.
Types of participants
We required that a majority of the participants should be within
the age range 18 to 65 years and suffering from severe mental
illness, preferably as deﬁned by the National Institute of Mental
Health (NIMH 1987) but, in the absence of that, from diagnosed
illness such as schizophrenia, schizophrenia-like disorders, bipolar
disorder or serious affective disorders. We did not consider sub-
stance abuse to be a severe mental illness in its own right, however
we did feel that studies should remain eligible if they dealt with
people with dual diagnoses, that is those with severe mental illness
plus substance abuse. We would not have included studies focus-
ing on dementia, personality disorder and mental retardation as
they were not covered by our deﬁnition of severe mental disorder.
Types of interventions
1. Physical health care monitoring
1.1 General physical health care monitoring in addition to
standard care
Monitoring can be any means of observation, supervision, keep-
ing under review, measuring or testing at intervals. We deﬁned
’physical health’ as ’soundness of body’ as opposed to the World
Health Organization’s deﬁnition of health which includes mental
and social well being (WHO 1948).
1.2 Focused physical health care monitoring
Adherence to speciﬁc guidance for example as a result of an iden-
tiﬁed illness (blood sugar in diabetes) or as a result of pharmaco-
logical treatment (weight gain with an atypical antipsychotic) in
addition to standard care.
2. Standard care
Care in which physical health monitoring is not speciﬁcally em-
phasised above and beyond care that would be expected for people
not suffering from severe mental illness.
3. Variations in delivery
We consider that there may be important studies comparing dif-
ferent types of monitoring delivered in several ways. We are in-
terested in these studies and will endeavour to include them in a
relevant comparison.
• Differences in who undertakes the monitoring - self
monitoring versus monitoring by healthcare professional.
• Differences in complexity of monitoring - simple routine
check or test versus complex check or test.
• Differences in focus of checks - speciﬁc health check versus
non-speciﬁc health check.
• Differences in pattern of checking - once only checks versus
regular checks.
• Differences in guidance followed - one set of guidelines
versus another.
Types of outcome measures
For the purposes of this review we divided the outcomes into four
time periods: i. immediate (within one week), ii. short term (one
week to six months), iii. medium term (six months to one year),
and iv. long term (over one year).
Primary outcomes
1. Physical health - immediate
1.1 Failure to identify a disease state and provide appropriate treat-
ment
1.2 Failure to effectively manage a known disease state
1.3 Failure to act on known risk factors
1.4 Unchecked adverse effects of treatment
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2. Quality of life
2.1 Loss of independence
2.2 Loss of Activities of Daily Living (ADL) skills
2.3 Chronic pain
2.4 Immobility
2.5 Loss of earnings
2.6 Loss of social status
2.7 Healthy days
Secondary outcomes
1. Physical health - periods other than immediate
1.1 Failure to identify a disease state and provide appropriate treat-
ment
1.2 Failure to improve management of a known disease state
1.3 Failure to act on known risk factors
1.4 Unchecked side-effects of treatment
2. Adverse events
2.1 Number of participants with at least one adverse effect
2.2 Clinically important speciﬁc adverse effects (cardiac effects,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count)
2.3 Average endpoint in speciﬁc adverse effects
2.4 Average change in speciﬁc adverse effects
2.5 Death - natural or suicide
3. Service use
3.1 Hospital admission
3.2 Emergency medical treatment
3.3 Use of emergency services
4. Financial dependency
4.1 Claiming unemployment beneﬁt
4.2 Claiming ﬁnancial assistance because of a physical disability
5. Social
5.1 Unemployment
5.2 Social Isolation as a result of preventable incapacity
5.3 Increased burden to caregivers
6. Quality of life or general functioning
6.1 No clinically important change in general quality of life
6.2 Average endpoint general quality of life score
6.3 Average change in general quality of life score
6.4 No clinically important change in general functioning
6.5 Average endpoint general functioning score
6.6 Average change in general functioning score
7. Economic
7.1 Increased costs of health care
7.2 Days off sick from work
7.3 Reduced contribution to society
7.4 Family claiming carer’s allowance
8. Leaving the studies early (any reason, adverse events,
inefficacy of treatment)
9. Global state
9.1 No clinically important change in global state (as deﬁned by
the individual studies)
9.2 Relapse (as deﬁned by the individual studies)
10. Mental state (with particular reference to the positive and
negative symptoms of schizophrenia)
10.1 No clinically important change in general mental state score
10.2 Average endpoint general mental score
10.3 Average change in general mental state score
10.4Noclinically important change in speciﬁc symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia)
10.5 Average endpoint speciﬁc symptom score
10.6 Average change in speciﬁc symptom score
11.Satisfaction with treatment
11.1 Participant satisfaction with treatment
11.2 Carer satisfaction with treatment
12. Summary of findings table
In future updates we will use the GRADE approach to interpret
ﬁndings (Schünemann 2008) and we will use the GRADEproﬁler
to import data from Review Manager (RevMan) to create ’Sum-
mary of ﬁndings’ tables. These tables provide outcome speciﬁc
information concerning the overall quality of evidence from each
included study in the comparison, the magnitude of effect of the
interventions examined, and the sum of the available data on all
outcomes we rated as important to patient care and decision mak-
ing. We selected the following main outcomes for inclusion in the
summary of ﬁndings table.
• Physical health - immediate
Failure to identify a disease state andprovide appropriate treatment
Failure to effectively manage a known disease state
• Quality of life
Loss of ADL skills
• Adverse event
Clinically important speciﬁc adverse effects (cardiac effects, death,
movement disorders, prolactin increase and associated effects,
weight gain, effects on white blood cell count)
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Death - natural or suicide
• Economic
Increased costs of health care
• Social
Social Isolation as a result of preventable incapacity
Search methods for identification of studies
Electronic searches
For the previous search please see Appendix 1.
The Trials Search Co-ordinator, Samantha Roberts, searched the
Cochrane Schizophrenia Group Trials Register (October 2012)
using the phrase:
[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or
*AIDS* or *Tobacc* or *Smok* or *sex* or *medical* or *dental*
or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutri-
tion* or *advice* or *monitor* in title of REFERENCES) AND
(*education* OR *health promot* OR *preventi* OR *motivate*
or *advice* or *monitor* in interventions of STUDY)].
The Cochrane Schizophrenia Group Trials Register is compiled
by systematic searches of major databases and handsearches of
relevant journals and conference proceedings (seeGroup Module).
Incoming trials are assigned to relevant existing or new review
titles.
Searching other resources
1. Unsystematic search
We undertook unsystematic searches of a sample of the com-
ponent databases (BNI, CINHAL, EMBASE, MEDLINE and
PsycINFO) to determine if any material may have been over-
looked.We searched the databases using speciﬁc phrases (’physical
health’, ’monitoring’ and ’mental illness’) as the searches that create
the Cochrane Schizophrenia Group Trials Register are methodol-
ogy speciﬁc. We did not identify any relevant trials.
2. Reference searching
We inspected the references of all identiﬁed studies for other rele-
vant studies.
3. Personal contact
We planned to contact the ﬁrst author of each included study
for information regarding unpublished trials; however, no studies
were included in this review.This will be done as and when future
updates of this review identify relevant studies.
Data collection and analysis
In this update there are a few changes to the data collection and
analysis methods to reﬂect changes in the Cochrane Schizophre-
nia Group’s template methodology. For comparison please see
Appendix 2.
Selection of studies
For the original version, review authors GT, AC and SM screened
the results of the electronic search.MB inspected a random sample
of these results, comprising 10% of the total. The principal re-
viewer (GT) and co-reviewer (AC) inspected all abstracts of stud-
ies identiﬁed through screening and identiﬁed potentially relevant
reports. Where disagreement occurred we resolved this by discus-
sion, and where there was still doubt we acquired the full article
for further inspection. We then requested the full articles of rel-
evant reports for reassessment and carefully inspected them for a
ﬁnal decision on inclusion (see Criteria for considering studies for
this review). In turn, GT and AC inspected all full reports and
independently decided whether they met the inclusion criteria.
We were not blinded to the names of the authors, institutions
or journal of publication. Where difﬁculties or disputes arose, we
asked author MB for help and if it was impossible to decide these
studies were added to those awaiting assessment and the authors
of the papers were contacted for clariﬁcation.
For the 2012 update, two review authors (MW and JX) screened
the results of the electronic search. GT and AC were consulted
on all potentially relevant reports and a consensus was reached
between all authors in deciding to include or exclude a particular
study.
Data extraction and management
1. Extraction
For the original version of this review, no studies were included.
If studies had been available, authors GT and AC would have
independently extracted data from the included studies. GT and
ACwouldhave discussed any disagreement, documenteddecisions
and, if necessary, contacted the authors of studies for clariﬁcation.
With remainingproblemsMBwouldhave helped clarify issues and
we would have documented our ﬁnal decisions. Data presented
only in graphs or ﬁgures would have been extracted whenever
possible, but only included if two review authors independently
had the same result. Attempts would have been made to contact
authors through an open-ended request in order to obtain any
missing informationor for clariﬁcationwhenever necessary.Where
possible, the review authors would have extracted data relevant to
each component centre of multi-centre studies separately.
Again, for the 2012 update no studies were included and no data
extracted, so the above methods were not applied.
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2. Management
2.1 Forms
For the original version, GT and AC would have extracted data
onto standard, simple forms. No data were extracted for the 2012
update.
2.2 Scale-derived data
We planned to include continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument had not been written or modiﬁed by
one of the trialists for that particular trial.
Ideally the measuring instrument should either be: i. a self-report,
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly; for future
updates of this review we will note whether or not this is the case
in the description of studies.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint), which can be difﬁcult in
unstable and difﬁcult to measure conditions such as schizophre-
nia. We decided to primarily use endpoint data, and only use
change data if the former were not available. For future updates
we will combine endpoint and change data in the analysis and use
mean differences (MD) rather than standardised mean differences
throughout (Higgins 2011, Chapter 9.4.5.2).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not nor-
mally distributed. To avoid the pitfall of applying parametric tests
to non-parametric data, we aimed to apply the following standards
to all data before inclusion: a) standard deviations and means are
reported in the paper or obtainable from the authors; b) when a
scale starts from the ﬁnite number zero, the standard deviation,
when multiplied by two, is less than the mean (as otherwise the
mean is unlikely to be an appropriate measure of the centre of the
distribution (Altman 1996)); c) if a scale started from a positive
value (such as the PANSS, which can have values from 30 to 210),
we would have modiﬁed the calculation described above to take
the scale starting point into account. In these cases skew is present
if 2SD > (S - S min), where S is the mean score and S min is the
minimum score. Endpoint scores on scales often have a ﬁnite start
and endpoint and these rules can be applied. Had we included any
studies we would have entered skewed endpoint data from studies
of fewer than 200 participants as ’other data’ within the Data and
analyses rather than into a statistical analysis. Skewed endpoint
data pose less of a problem when looking at the mean if the sample
size is large; we would have entered such data into syntheses, and
will do so in future updates if relevant studies are identiﬁed.
When continuous data are presented on a scale that includes a
possibility of negative values (such as change data), it is difﬁcult
to tell whether the data are skewed or not and skewed change data
will be entered into analyses in future updates.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (for example mean days per month).
2.6 Conversion of continuous to binary outcomes
In future updates of this review we will, where possible, make an
effort to convert outcomemeasures to dichotomous data. This can
be done by identifying cut-off points on rating scales and dividing
participants accordingly into ’clinically improved’ or ’not clinically
improved’. It is generally assumed that if there is a 50% reduction
in a scale-derived score such as the Brief Psychiatric Rating Scale
(BPRS, Overall 1962) or the Positive and Negative Syndrome
Scale (PANSS, Kay 1986), this could be considered as a clinically
signiﬁcant response (Leucht 2005; Leucht 2005a). If data based
on these thresholds are not available, we will use the primary cut-
off presented by the original authors in future updates.
2.7 Direction of graphs
In future updates we will enter data in such a way that the area
to the left of the line of no effect indicates a favourable outcome
for physical health monitoring. Where keeping to this makes it
impossible to avoid outcome titles with clumsy double-negatives
(for example ’Not unimproved’) we plan to report data where the
left of the line indicates an unfavourable outcome. This will be
noted in the relevant graphs in future updates.
Assessment of risk of bias in included studies
For this update, review authors JS and MW were to work inde-
pendently by using criteria described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) to assess trial
quality. This new set of criteria is based on evidence of associa-
tions between overestimate of effect and high risk of bias of the
trial report, such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.
If inadequate details of randomisation and other characteristics
of trials were provided, we would have attempted to contact the
authors of the studies in order to obtain additional information.
Had we identiﬁed studies relevant to this review we would have
noted the level of risk of bias in both the text of the review and
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in a Summary of ﬁndings for the main comparison. This will be
done in future updates if relevant studies are identiﬁed.
Measures of treatment effect
1. Binary data
We had planned to calculate a standard estimation of the risk ratio
(RR) and its 95% conﬁdence interval (CI) for binary outcomes.
It has been shown that RR is more intuitive (Boissel 1999) than
odds ratios and that odds ratios tend to be interpreted as RRs by
clinicians (Deeks 2000). The Number Needed to Treat or Harm
(NNT/H) statistic with its CI is intuitively attractive to clinicians
but is problematic both in its accurate calculation in meta-anal-
yses and the interpretation (Hutton 2009). For future updates if
relevant studies are identiﬁed, for binary data presented in the
’Summary of ﬁndings’ table(s), where possible, we will calculate
illustrative comparative risks.
2. Continuous data
It was planned that we would estimate mean difference (MD) be-
tween groups for continuous outcomes. In future updates we pre-
fer not to calculate effect size measures (standardised mean differ-
ence (SMD)). However, if scales of very considerable similarity are
used, we will presume there is a small difference in measurement
and we will calculate effect size and transform the effect back to
the units of one or more of the speciﬁc instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ cluster randomisation (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data pose problems. Authors often fail to account for
intra-class correlation in clustered studies, leading to a unit of
analysis error (Divine 1992) whereby P values are spuriously low,
CIs unduly narrow and statistical signiﬁcance overestimated. This
causes type I errors (Bland 1997; Gulliford 1999).
In future updates, where clustering is not accounted for in pri-
mary studies, we will present the data in a table with a (*) sym-
bol to indicate the presence of a probable unit of analysis error.
In subsequent versions of this review we will seek to contact the
ﬁrst authors of studies to obtain intra-class correlation coefﬁcients
for their clustered data and to adjust for this by using accepted
methods (Gulliford 1999). Where clustering has been incorpo-
rated into the analysis of primary studies, we will present these
data as if from a non-cluster randomised study but adjust for the
clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the intra-class correlation coefﬁcient (ICC)
(Design effect = 1 + (m - 1) * ICC) (Donner 2002). If the ICC is
not reported it will be assumed to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed taking into ac-
count intra-class correlation coefﬁcients and the relevant data doc-
umented in the report, synthesis with other studies would be pos-
sible using the generic inverse variance technique, which will be
used in future updates.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It
occurs if an effect (for example pharmacological, physiological or
psychological) of the treatment in the ﬁrst phase is carried over to
the second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason, cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, in
future updates we will only use the data from the ﬁrst phase of
cross-over studies.
3. Studies with multiple treatment groups
For future updates, it is planned that where a study involves more
than two treatment arms, if relevant, we will present the additional
treatment arms in comparisons. If the data are binary we will add
these and combine them within the two-by-two table. If the data
are continuous we will combine the data following the formula
in section 7.7.3.8 (Combining groups) of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). Where the
additional treatment arms are not relevant, we will not reproduce
these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). For future updates of this review, for any particular out-
come, should more than 50% of data be unaccounted for we will
not reproduce these data or use them within analyses. If, however,
more than 50% of those in one arm of a study are lost but the total
loss is less than 50%, we will address this within the ’Summary
of ﬁndings’ table(s) by down-rating their quality. Finally, we will
also downgrade quality within the ’Summary of ﬁndings table(s)
should the loss be 25% to 50% in total.
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2. Binary
In the case where attrition for a binary outcome is between 0% and
50%, and where these data are not clearly described, for future up-
dates we will present the data on a ’once randomised always anal-
yse’ basis (an intention-to-treat analysis). Those leaving the study
early are all assumed to have the same rates of negative outcome as
those who completed, with the exception of the outcome of death
and adverse effects. For these outcomes the rate of those who stay
in the study, in that particular arm of the trial, will be used for
those who did not. We will undertake a sensitivity analysis testing
how prone the primary outcomes are to change when data only
from people who completed the study to that point are compared
to the intention-to-treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between
0% and 50%, and data only from people who completed the study
to that point are reported, we will in future updates reproduce
these in updated versions of this review if relevant studies with
useable data are identiﬁed.
3.2 Standard deviations
In future updates of this review, if standard deviations are not re-
ported we will ﬁrst try to obtain the missing values from the au-
thors. If not available, where there aremissingmeasures of variance
for continuous data but an exact standard error and conﬁdence
interval are available for group means, and either the P value or
t value is available for differences in the mean, we can calculate
them according to the rules described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011): when only
the standard error (SE) is reported, standard deviations (SDs) are
calculated by the formula SD = SE * square root (n). Chapters
7.7.3 and 16.1.3 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011) present detailed formulae for es-
timating SDs from P values, t or F values, CIs, ranges or other
statistics. If these formulae do not apply, we will calculate the SDs
according to a validated imputation method which is based on
the SDs of the other included studies (Furukawa 2006). Although
some of these imputation strategies can introduce error, the alter-
native would be to exclude a given study’s outcome and thus to
lose information. We nevertheless will examine the validity of the
imputations in a sensitivity analysis excluding the imputed values.
3.3 Last observation carried forward
We anticipate that in some studies the method of last observation
carried forward (LOCF) will be employed within the study report.
As with all methods of imputation to deal with missing data,
LOCF introduces uncertainty about the reliability of the results
(Leucht 2007). Therefore, where LOCF data have been used in
the trial, if less than 50% of the data have been assumed we will
present and use these data and indicate that they are the product
of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
In future updates, we will consider all included studies initially,
without seeing comparison data, to judge clinical heterogeneity.
We will simply inspect all studies for clearly outlying people or
situations which we had not predicted would arise. When such
situations or participant groups arise in future updates wewill fully
discuss them.
2. Methodological heterogeneity
In future updates we will consider all included studies initially,
without seeing comparison data, to judge methodological hetero-
geneity.Wewill simply inspect all studies for clearly outlyingmeth-
ods which we had not predicted would arise. When such method-
ological outliers arise in updates, we will fully discuss them.
3. Statistical heterogeneity
3.1 Visual inspection
We plan to visually inspect graphs of included studies in future
updates to investigate the possibility of statistical heterogeneity.
3.2 Employing the I2 statistic
We had planned to investigate heterogeneity between studies by
considering the I2 statistic alongside the Chi2 test P value. The I
2 statistic provides an estimate of the percentage of inconsistency
thought to be due to chance (Higgins 2003). The importance of
the observed value of I2 depends on: i. magnitude and direction
of the effects, and ii. strength of evidence for heterogeneity (for
example P value from Chi2 test, or a CI for the I2 statistic). An I
2 estimate greater than or equal to around 50%, accompanied by
a statistically signiﬁcant Chi2 statistic, is interpreted as evidence
of substantial levels of heterogeneity (Higgins 2011). If relevant
studies are identiﬁed in updated versions of this review where sub-
stantial levels of heterogeneity are found in the primary outcome,
we plan to explore the reasons for the heterogeneity (Subgroup
analysis and investigation of heterogeneity).
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Assessment of reporting biases
Reporting biases arise when the dissemination of research ﬁndings
is inﬂuenced by the nature and direction of the results (Egger
1997). These are described in section 10 of theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011).We are aware
that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We do not
plan to use funnel plots for outcomes where there are 10 or fewer
studies, or where all studies were of a similar size, in updates of
this review. In other cases where funnel plots are possible, we will
seek statistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference of
ﬁxed-effect or random-effects models. The random-effects model
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
signiﬁcant heterogeneity. There is, however, a disadvantage to the
random-effects model as it puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inﬂate or deﬂate the effect size.
We will choose the ﬁxed-effect model for all analyses in future
updates of this review. The reader will be, however, able to choose
to inspect the data using the random-effects model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses, only primary outcomes
1.1 Clinical state, stage or problem
We proposed to undertake this review and provide an overview
of the effects of physical health monitoring for people with
schizophrenia in general. We anticipated no subgroup analyses.
2. Investigation of heterogeneity
For future updates, if inconsistency was high we will report this.
First, we will investigate whether the data have been entered cor-
rectly. Second, if the data are correct, we will visually inspect the
graph and successively remove studies outside the company of the
rest to see if homogeneity is restored. For this review we have de-
cided that should this occur with data contributing no more than
around 10% of the total weighting to the summary ﬁnding, we
would present the data. If not, then we will not pool the data and
will discuss the issues. We know of no supporting research for this
10% cut-off, but we use prediction intervals as an alternative to
this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity is
obvious, we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to them.
Sensitivity analysis
We will, in future, apply all sensitivity analyses to the primary
outcomes of this review.
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For future up-
dates of this review, for the primary outcomes we will include these
studies and if there was no substantive difference when the implied
randomised studies were added to those with better descriptions
of randomisation then we would enter all data from these studies.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up and missing SDs (see Dealing with missing data), we will
compare the ﬁndings for the primary outcomes when we use our
assumptions compared with the complete data only. We plan to
undertake a sensitivity analysis testing how prone the results are to
change when ’completer’ data only are compared to the imputed
data using the above assumption. If future updates ﬁnd there is a
substantial difference, we will report the results and discuss them
but will continue to employ our assumption.
3. Risk of bias
We plan to analyse the effects of excluding trials that are judged
to be at high risk of bias across one or more of the domains of ran-
domisation (implied as randomised with no further details avail-
able), allocation concealment, blinding and outcome reporting for
the meta-analysis of the primary outcome. If the exclusion of trials
at high risk of bias does not substantially alter the direction of
effect or the precision of the effect estimates, then we will include
the data from these trials in the analysis.
4. Imputed values
We will also undertake a sensitivity analysis to assess the effects of
including data from trials where we used imputed values for ICC
in calculating the design effect in cluster randomised trials.
If data of this kind are included in future updates of this review,
we will note substantial differences in the direction or precision
of effect estimates in any of the sensitivity analyses listed above.
We will not pool data from the trials with imputed values with
the other trials contributing to the outcome but present them
separately.
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5. Fixed-effect and random-effects models
We plan to synthesise data in future updates of this review using
a ﬁxed-effect model.
R E S U L T S
Description of studies
Results of the search
The initial search of the Cochrane Schizophrenia Group Trials
Register in 2009 was a combined search designed to identify stud-
ies which would be relevant to this review and to another sister
review on physical health advice for people with serious mental
illness (Tosh 2013). The search identiﬁed 2382 references (from
1558 studies). After examining the reports, only three were suit-
able for further examination and all were excluded. Forty-two ad-
ditional studies were identiﬁed in the 2012 update, 17 under-
went detailed evaluation and all were excluded apart from one
which is ongoing (Figure 1). Despite the fact that the Cochrane
Schizophrenia Group Trials Register is compiled from large com-
prehensive and systematic searches for trials, we undertook unsys-
tematic searches of a sample of the component databases (BNI,
CINHAL, EMBASE, MEDLINE and PsycINFO) to determine
if any material may have been overlooked. We searched using spe-
ciﬁc phrases (’physical health’, ’monitoring’ and ’mental illness’) as
the searches that create the Cochrane Schizophrenia Group Trials
Register are methodology speciﬁc.We did not identify any further
relevant trials.
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Figure 1. Study flow diagram for 2012 update..
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Included studies
There are no still no studies that have met the criteria for this
review.
Excluded studies
One trial was excluded on the basis that it is an ongoing trial,
in the recruitment stage, which is focusing on the monitoring of
mental health parameters and not physical health (Jürgens 2008).
Another trial had to be excluded as it monitored the effects of a
pharmacological intervention on a physical health parameter (Lan
2007). The third exclusion was on the basis that the trial com-
pared the effects of different ways of monitoring a speciﬁc anxiety
symptom and did not look at a physical health (Rostow 1980).
Of the 11 studies that were excluded in the 2012 search, eight did
not focus on general physical health as a primary outcome (Becker
2005; Bushe 2010; Carmeli 2012; Kluge 2012; Krakowski 2011;
Peuskens 2011; Tanasiewicz 2011; Lin 2010). Two studies had no
standard care comparisons (Ozguven 2011; Peuskens 2011) and
one provided data on the prevalence of morbidities in the absence
of an intervention (Saddichha 2011). For more details please see
Characteristics of excluded studies.
1. Awaiting assessment
There are no studies awaiting assessment.
2. Ongoing studies
We identiﬁed one ongoing study (ISRCTN63382258). This trial,
for which a protocol is available, is monitoring the oral and dental
health of people with serious mental illness, is a cluster randomised
trial from the UK and should report in 2015.
Risk of bias in included studies
There were no studies that fulﬁlled the criteria for inclusion. We
did not exclude any studies on the grounds of poor methodology.
Allocation
No studies met the criteria for this review.
Blinding
No studies met the criteria for this review.
Incomplete outcome data
No studies met the criteria for this review.
Selective reporting
No studies met the criteria for this review.
Other potential sources of bias
There were no studies that fulﬁlled the criteria for inclusion. We
did not exclude any studies on the grounds of poor methodology.
Effects of interventions
See: Summary of findings for the main comparison Physical
health monitoring compared to no monitoring for people with
serious mental illness
Currently we know of no fully reported randomised studies de-
scribing the effects of monitoring the physical health care of peo-
ple with serious mental illnesses.
D I S C U S S I O N
Note: no studies are included in this review, one study is ongoing.
Summary of main results
Please also see Summary of ﬁndings for the main comparison.
1. No trial-based evidence
Current medical practice in the UK is led by guidance from bodies
such as the National Institute of Clinical Excellence (NICE 2006)
and The Maudsley Prescribing Guidelines (Taylor 2009), who
predominantly base their guidance on little more than anecdotal
evidence, consensus of opinion (Marder 2004) and good inten-
tions. The association between schizophrenia and poor physical
health is well established (Robson 2007) and, taken at face value,
current guidance seems to make sense. Unfortunately history is
littered with treatments and policies which ’seemed like a good
idea at the time’ but which, with the beneﬁt of hindsight, were at
best ineffective and at worst resulted in harm. Extreme examples
of well intentioned treatments could be trepanation for epilepsy
(Adams 1856), ice-pick lobotomies for unruly children (El-Hai
2008), or radium water for high blood pressure (JAMA 1925).
More contemporary and subtle is the wide use of oil of evening
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primrose oil for many ailments when evidence for efﬁcacy is poor
(Bayles 2009). This could mean that hopes are raised inappropri-
ately and, perhaps, other more effective treatments are avoided.
When it comes to mental health policy, the early legislation for the
Care Programme Approach in the UK was well intentioned but
ultimately it imported a largely wasteful and ineffective package of
care from the US (Marshall 1996; Marshall 1998) at a time when
even those in the US had found it necessary to substantially evolve
the approach into a more effective package (Assertive Outreach).
In more recent times the evidence to support the view that spe-
cialist mental health services such as Dual Diagnosis Teams, Early
Intervention or AssertiveOutreachTeams are more beneﬁcial than
appropriately supported Community Mental Health Teams is not
as strong as would have been originally thought (Ley 2000).
Care, and the time of people with serious mental illness, are too
costly to waste on ideas that are not of proven beneﬁt. Vulnerable
people with serious mental illness should surely expect that all
aspects of their care have been subject to some degree of evaluation.
Overall completeness and applicability of
evidence
No studies met the criteria for this review.
Quality of the evidence
The three studies we obtained for closer inspection were not ex-
cluded because of issues of quality. We were unable to ﬁnd any
studies that were vaguely relevant, regardless of whether they were
high or poor quality.
Potential biases in the review process
The search strategies both for the Cochrane Schizophrenia Group
Trials Register (October 2009 and October 2012) and in our un-
systematic search (see: Searching other resources) should have been
robust enough to detect relevant studies. It is possible that we
have failed to identify small studies but we think it unlikely that
we would have missed large trials. Studies published in languages
other than English, and those with equivocal results, are often dif-
ﬁcult to ﬁnd (Egger 1997). Our search was biased by the use of
English phrases. However, given that the Cochrane Schizophre-
nia Group Trials Register covers many languages but is indexed
in English we feel that we would not have missed many studies
within the register. For example, the search uncovered 101 studies
for which the title was only available in Chinese characters. These
were checked for relevance by a Chinese speaking colleague (Jun
Xia) and none were identiﬁed as possibly relevant to this review.
Agreements and disagreements with other
studies or reviews
The only other similar systematic review that we are aware of is
Bradshaw 2005, which investigated the efﬁcacy of healthy living
interventions for people with schizophrenia. They too identiﬁed
no trials of monitoring and we agree that rigorous studies are
needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Due to the lack of evidence for the current guidance around physi-
cal health monitoring it is important that people with schizophre-
nia expect clinicians to explain their intentions clearly. It would
seem reasonable that people with schizophrenia are given the
choice of whether they want to be monitored in this way, or
whether they would want to add to the body of evidence by being
part of a well designed trial from which outcomes relevant to their
care would be derived.
2. For clinicians
Clinicians should be aware that current guidance on monitoring
the physical health for people with serious mental illness is not
supported by any evidence from randomised controlled trials. It
would seem reasonable that this is explained to people with se-
rious mental illness. It is possible clinicians are expending much
effort, time and ﬁnancial expenditure on monitoring the physical
health of people with serious mental illnesses which is unneces-
sary, intrusive and costly. It is possible that the monitoring may
differ depending on who is undertaking the procedure. For exam-
ple, psychiatrists may not be as good at it as general practitioners.
Clinicians should, therefore, take a much more critical view of
current guidance and attempt to initiate or get involved with any
studies which could provide an evidence base for this practice.
3. For policy makers or managers
Current policies and guidelines are bornout of good intentions and
“the evidence for such interventions remains uncertain” (NICE
2006). This puts policy makers in a difﬁcult position of galvanis-
ing consensus rather than evidence. There remains an enduring
concern that “L’enfer est plein de bonnes volontés ou désirs” (Hell
is full of good intentions or wishes) (St. Bernard of Clairvaux 1150
quoted in Ammer 2003). Policy makers or managers should be
better at recommending an active research interest in this area.
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These conclusions have not been altered after completing the as-
sessment of the 42 studies identiﬁed in the most recent 2012
search.
Implications for research
1. General
We could not identify any randomised trials that assessed the ef-
fectiveness of physical health monitoring in people with serious
mental illness and which contradicted the view that current guid-
ance and practice are based on good intentions and expert opinion.
Basing care solely on evidence from trials is not realistic (Cooper
2003;Tanenbaum 2005), howevermany treatments or approaches
that are not well evaluated are given to people when it is actually
entirely possible to evaluate these approaches. Healthcare profes-
sionals may be doing far more good than they realise, or far more
harm. As part of a duty of care, we argue that ’what could be
known, should be known’.
2. Specific
2.1 Reviews
This review should be the focus of regular updates. One new trial
will completely change the overview.
The excluded studies do suggest other reviews that may be of
interest (Table 2).
2.2 Trials
We realise that much thought and care goes into the design of
randomised studies. We have, however, also given this issue some
consideration and suggest what we think to be a feasible design;
please see Table 3.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Becker 2005 Allocation: cluster randomisation.
Participants: majority with affective disorder, 1/3 with schizophrenia, remainder with another IDC-Chapter V
diagnosis
Intervention: education in outcome management - not physical health monitoring
Bushe 2010 Allocation: randomised.
Participants: people diagnosed with schizophrenia.
Intervention: effects of olanzapine or quetiapine on glucose, lipids and weight - not physical health monitoring
Carmeli 2012 Allocation: randomised.
Participants: people diagnosed with schizophrenia.
Intervention: looked at whether increase glutathione levels modulate EEG synchronization - not physical health
monitoring
Jürgens 2008 Allocation: randomised.
Participants: people diagnosed with schizophrenia.
Intervention: genotype monitoring versus intense clinical monitoring - not physical health monitoring
Kluge 2012 Allocation: randomised, double-blind.
Participants: people diagnosed with schizophrenia.
Intervention: effects of clozapine and olanzapine on sleep propensity - not physical health monitoring
Krakowski 2011 Allocation: randomised, double-blind.
Participants: people diagnosed with schizophrenia.
Intervention: effects of clozapine, olanzapine and haloperidol on cholesterol levels and cognition - not physical
health monitoring
Lan 2007 Allocation: randomised.
Participants: people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder.
Intervention: monitoring of the effect of aripiprazole and aripiprazole plus haloperidol on prolactin levels - not
physical health monitoring
Lin 2010 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: effect of health intervention on constipation - not physical health monitoring
Nielsen 2012 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: evaluating capillary blood sampling device versus venous sampling in patients taking clozapine -
not physical health monitoring
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(Continued)
Ozguven 2011 Allocation: randomised.
Participants: women with unclear diagnosis (within spectrum of atypical antipsychotic monotherapy)
Intervention: measured effects of olanzapine and quetiapine on weight gain, BMI, lipid proﬁle - no standard
care comparison
Peuskens 2011 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: evaluated the effect of sertindole or risperidone on metabolic proﬁle - no standard care comparison
Rostow 1980 Allocation: randomised.
Participants: people with “compulsive or persistent pacing”, not necessarily having a diagnosis of serious mental
illness
Saddichha 2011 Allocation: not randomised, cross-sectional survey.
Participants: patients diagnosed with schizophrenia or schizoaffective disorder
Intervention: reported prevalence of diabetes hypertension and obesity on patients on antipsychotic medications
Strom 2011 Allocation: randomised.
Participants: patients with schizophrenia.
Intervention: death associated with olanzapine and ziprasidone use
Tanasiewicz 2011 Allocation: randomised.
Participants: people with schizophrenia on atypical and classical neuroleptics
Intervention: oral hygienic training - not physical health monitoring
Characteristics of ongoing studies [ordered by study ID]
ISRCTN63382258
Trial name or title Three Shires Early Intervention Dental Trial (ISRCTN63382258).
Methods Allocation: cluster randomised.
Blindness: none.
Duration: 12 months.
Participants Diagnosis: serious mental illness.
N = 1074.
Age: >18 years.
Sex: not reported.
History: not reported.
Exclusion: any Early Intervention in Psychosis team that does not wish to take part, any individual care co-
ordinator or service user within a team that does not wish to take part, any service user aged less than 18 years
old at randomisation
Setting: multi-centre, community; Early Intervention in Psychosis teams, UK
Interventions 1. dental awareness training for care co-ordinators + an oral health checklist for service users + standard care
2. standard care.
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ISRCTN63382258 (Continued)
Outcomes Visit to dentist within one year of exposure to checklist.
Registration with a dentist.
Frequency of tooth brushing.
Reason for dental visit (routine versus for problem).
Quality of life (Oral Impacts on Daily Performance, OIDP).
Economic data.
Leaving the study.
Starting date February 2012.
Contact information Miss Hannah Jones, CLAHRC-NDL, Institute of Mental Health, University of Nottingham, Triumph Road,
Nottingham, NG7 2TU, UK. Email: Hannah.Jones@nottingham.ac.uk
Notes Study protocol available. Contacted author to request data, data will be available September 2013
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Series of related reviews
Title Reference
Physical health care monitoring This review
General physical health advice Tosh 2011
Advice regarding smoking cessation Khanna 2012
Advice regarding oral health care Khokhar 2011
Advice regarding HIV/AIDs prevention Wright 2012
Advice regarding substance use Underway
Table 2. Reviews suggested by excluded studies
Broad issue Specific issue Excluded study Existing review
Antipsychotic adverse effects clozapine and olanzapine on
sleep propensity
Kluge 2012 Komossa 2010
Antipsychotic metabolic ad-
verse effects
aripiprazole and aripiprazole
plus haloperidol on prolactin
levels
Lan 2007
clozapine, olanzapine
and haloperidol on cholesterol
levels and cognition
Krakowski 2011 Asenjo 2010; Essali 2009
olanzapine and quetiapine on
weight gain, BMI, lipid proﬁle
Ozguven 2011 Komossa 2010
olanzapine or quetiapine on
glucose, lipids and weight
Bushe 2010
sertindole or risperidone on
metabolic proﬁle
Peuskens 2011 Komossa 2009
Education education in outcome manage-
ment
Becker 2005
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Table 2. Reviews suggested by excluded studies (Continued)
Physiological monitoring evaluating capillary blood sam-
pling device vs venous sampling
in patients taking clozapine
Nielsen 2012
genotype monitoring versus in-
tense clinical monitoring
Jürgens 2008
glutathione levels modulate
EEG-synchronization
Carmeli 2012
Specific physical health issue health intervention on consti-
pation
Lin 2010
oral hygienic training Tanasiewicz 2011 Khokhar 2011
Table 3. Suggested design of study
Methods Allocation: randomised, clearly described.
Blinding: single - particular to speciﬁc outcomes (see below).
Duration: 6 months.
Participants Diagnosis: schizophrenia, or any serious mental illness.
N=450.*
Age: any.
Sex: both.
History: any.
Interventions 1. General physical health care checklist (e.g. Physical Health Improvement Proﬁle see White 2009): administered
by Care Co-ordinator. N=150.
2. Speciﬁc aspect of physical health care checklist (e.g. BSDH 2000): administered by Care Co-ordinator. N=150.
3. Standard care: administered by Care Co-ordinator. N=150.
Outcomes Death.
Morbidity: serious or minor, categorised by type, rates of events - general or speciﬁc.
Healthy days.
Service use: visit to heath care practitioner.
Acceptability of checklist.
Compliance: with physical health care advice, including treatments.
Adverse effects: any.
Notes * For 20% difference between groups for a binary outcome to be highlighted with reasonable degree of conﬁdence
150 people are needed per group
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A P P E N D I C E S
Appendix 1. Previous search
1. Cochrane Schizophrenia Group Trials Register (October 2009)
The register was searched using the phrase:[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc*
or *Smok* or *sex* or *medical* or *dental* or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* or *advice* or
*monitor* in title of REFERENCES) AND (*education* OR *health promot* OR *preventi* OR *motivate* or *advice* or *monitor*
in interventions of STUDY)]
The Cochrane Schizophrenia Group’s Trials Register is compiled by systematic searches of major databases, handsearches of relevant
journals and conference proceedings (see Group Module). Incoming trials are assigned to relevant existing or new review titles.
Appendix 2. Previous data collection and analysis methods
1. Extraction
Authors GT and AC independently extracted data from included studies. Again, we discussed any disagreement, documented our
decisions and, if necessary, we contacted the authors of studies for clariﬁcation. With remaining problems MB helped clarify issues and
we documented our ﬁnal decisions. We extracted data presented only in graphs and ﬁgures whenever possible, we only included it if
two reviewers independently had the same result. We made attempts to contact authors through an open-ended request in order to
obtain any missing information or for clariﬁcation whenever necessary. Where possible, we extracted data relevant to each component
centre of multi-centre studies separately.
2. Management
2.1 Forms
GT and AC extracted data onto standard, simple forms.
2.2 Data from multi-centre trials
Where possible the authors veriﬁed independently calculated centre data against original trial reports.
3. Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument was not written or modiﬁed by one of the trialists for that particular trial; and
c. the measuring instrument is either i. a self-report or ii. completed by an independent rater or relative (not the therapist).
4. Endpoint versus change data
We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of
view. Change data are often not ordinal and are very problematic to interpret. If endpoint data were unavailable, we used change data.
5. Skewed data
Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests
to non-parametric data, we aim to apply the following standards to all data before inclusion: (a) standard deviations and means are
reported in the paper or obtainable from the authors; (b) when a scale starts from the ﬁnite number zero, the standard deviation,
when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the
distribution, (Altman 1996); (c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the
calculation described above will be modiﬁed to take the scale starting point into account. In these cases skew is present if 2SD>(S-S
min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a ﬁnite start and end point
and these rules can be applied. When continuous data are presented on a scale which includes a possibility of negative values (such as
change data), it is difﬁcult to tell whether data are skewed or not. We entered skewed data from studies of less than 200 participants
in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large,
and we entered skewed data from large sample sizes into syntheses.
6. Common measure
To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in
hospital, (mean days per year, per week or per month) to a common metric (e.g. mean days per month).
7. Conversion of continuous to binary
Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut-off points
on rating scales and dividing participants accordingly into ’clinically improved’ or ’not clinically improved’. It was generally assumed
that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the
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Positive and Negative Syndrome Scale (Kay 1986, Kay 1987), this could be considered as a clinically signiﬁcant response (Leucht 2005;
Leucht 2005a). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.
8. Direction of graphs
Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for physical
health monitoring.
9. Summary of ﬁndings table
We anticipate including the following outcomes in a summary of ﬁnding table.
1. Physical health - immediate
1.1 Failure to identify a disease state and provide appropriate treatment
1.2 Failure to effectively manage a known disease state
2. Quality of life
2.1 Loss of Activities of Daily Living (ADL) skills
3. Adverse event
3.1 Clinically important speciﬁc adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects,
weight gain, effects on white blood cell count)
3.2 Death - natural or suicide
4. Economic
4.1 Increased costs of health care
5. Social
5.1 Social Isolation as a result of preventable incapacity
Assessment of risk of bias in included studies
Again working independently, GT,AC and MB assessed risk of bias using the tool described in the Cochrane Collaboration Handbook
(Higgins 2008). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of
blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would have excluded studies where
allocation was clearly not concealed.
We did not include trials with high risk of bias (deﬁned as at least 3 out of 5 domains were categorised as ’No’) in the meta-analysis.
If the raters disagreed, the ﬁnal rating was made by consensus with the involvement of another member of the review group. Where
inadequate details of randomisation and other characteristics of trials are provided, we contacted the authors of the studies in order to
obtain further information. Non-concurrence in quality assessment was reported.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the random-effect risk ratio (RR) and its 95% conﬁdence interval (CI). It
has been shown that RR is more intuitive (Boissel 1999) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). Within the Summary of Findings table we assumed for calculation of the low risk groups that the lowest control risk
applied to all data. We did the same for the assumption of the highest risk groups. We used the Summary of Findings table to calculate
absolute risk reduction for primary outcomes.
2. Continuous data
2.1 Summary statistic
For continuous outcomes we estimated a ﬁxed-effect mean difference between groups. We preferred not to calculate effect size measures
(standardised mean difference SMD). However, in the case of where scales were of such similarity to allow presuming there was a small
difference in measurement, we calculated it and, whenever possible, we transformed the effect back to the units of one or more of the
speciﬁc instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as randomisation by clinician or practice) but analysis and pooling of clustered
data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a ’unit of analysis’
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error (Divine 1992) whereby p values are spuriously low, conﬁdence intervals unduly narrow and statistical signiﬁcance overestimated.
This causes type I errors (Bland 1997; Gulliford 1999).
Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a
probable unit of analysis error. In subsequent versions of this review we will seek to contact ﬁrst authors of studies to obtain intra class
correlation co-efﬁcient of their clustered data and to adjust for this by using accepted methods (Gulliford 1999). Where clustering had
been incorporated into the analysis of primary studies, we present these data as if from a non-cluster randomised study, but adjusted
for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a ’design
effect’. This is calculated using themean number of participants per cluster (m) and the intra class correlation co-efﬁcient (ICC) [Design
effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999).
If cluster studies has been appropriately analysed taking into account intra class correlation co-efﬁcient and relevant data documented
in the report, synthesis with other studies would have been possible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carryover effect. It occurs if an effect (e.g. pharmacological, physiological or psychological)
of the treatment in the ﬁrst phase is carried over to the second phase. As a consequence on entry to the second phase the participants
can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the
condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, we only used data of the ﬁrst
phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. Where
the additional treatment arms were not relevant, we did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow up data must lose credibility (Xia 2009). For any particular outcome should than 50% of data be
unaccounted, we did not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study
were lost, but the total loss was less than 50%, we marked such data with ’*’ to indicate that such a result may well be prone to bias.
2. Binary
In the case where attrition for a binary outcome is between 0 and 50% and where these data were not clearly described, we presented
data on a ’once-randomised-always-analyse’ basis (an intention to treat analysis). Those lost to follow up were all assumed to have
the same rates of negative outcome as those who completed, with the exception of the outcome of death. A sensitivity analysis was
undertaken testing how prone the primary outcomes were to change when ’completed’ data only were compared to the intention to
treat analysis using the above assumption.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between 0 and 50% and completer-only data were reported, we have reproduced
these.
3.2 Standard deviations
Where there are missing measures of variance for continuous data but exact standard error and conﬁdence interval are available for
group means , either ‘p’ value or ’t’ value are available for differences in mean, we calculated standard deviation value according to
method described in Section 7.7.3 of the Cochrane Handbook (Higgins 2008). If standard deviations were not reported and could
not be calculated from available data, we asked authors to supply the data. In the absence of data from authors, the mean standard
deviation from other studies was used.
3.3 Last observation carried forward
We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results.
Therefore, where LOCF data has been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and
indicated that they are the product of LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
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To judge clinical heterogeneity, we considered all included studies, initially without seeing comparison data. We simply inspected all
studies for clearly outlying situations or people which we had not predicted would arise. Should such situations or participant groups
arise these will be fully discussed.
2. Methodological heterogeneity
We considered all included studies initially, without seeing comparison data, to judgemethodological heterogeneity.We simply inspected
all studies for clearly outlying methods which we had not predicted would arise. Should such methodological outliers arise these will
be fully discussed.
3. Statistical
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of statistical heterogeneity.
3.2 Employing the I-squared statistic
Heterogeneity between studies was investigated by considering the I-squared method alongside the Chi2 ’p’ value. The I2 provides an
estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I
2 depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. ’p’ value from Chi2 test, or a
conﬁdence interval for I2).
I2 estimate greater than or equal to 50% accompanied by a statistically signiﬁcant Chi2 statistic, was interpreted as evidence of substantial
levels of heterogeneity (Section 9.5.2 - Higgins 2008) and reasons for heterogeneity were explored. If the inconsistency was high and
the clear reasons were found, we presented data separately.
Assessment of reporting biases
Reporting biases arise when the dissemination of research ﬁndings is inﬂuenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook (Higgins 2008). We are aware that funnel plots may be useful in
investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where
there were ten or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought
statistical advice in their interpretation.
Data synthesis
Where possible we employed a random-effect model for analyses. We understand that there is no closed argument for preference for use
of ﬁxed or random-effect models. The random-effect method incorporates an assumption that different studies are estimating different,
yet related, intervention effects. According to our hypothesis of an existing variation across studies, to be explored further in the meta-
regression analysis despite being cautious that that random-effects methods does put added weight onto the smaller of the studies - we
favoured using random-effect model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We anticipate no sub-group analyses.
2. Investigation of heterogeneity
2.1 Unanticipated heterogeneity
Should unanticipated clinical or methodological heterogeneity be obvious we will simply state hypotheses regarding these for future
reviews or versions of this review. We do not anticipate undertaking analyses relating to these.
2.2 Anticipated heterogeneity
We are concerned that focused physical health care monitoring may have different effects than a more general approach. We therefore
anticipate some heterogeneity for the primary outcomes and propose to summate all data but also present them separately.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they are described in some way as to imply randomisation. For the primary outcomes
we included these studies and if there was no substantive difference when we added the implied randomised studies to those with better
description of randomisation, we then employed all data from these studies.
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2. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to follow up (see Dealing with missing data) we compared the ﬁndings of
the primary outcomes where we used our assumption and compared with completer data only. If there was a substantial difference, we
reported results and discussed them but continue to employ our assumption.
WH A T ’ S N E W
Last assessed as up-to-date: 1 December 2012.
Date Event Description
18 November 2013 New citation required but conclusions have not
changed
Update completed, no change to conclusions.
27 June 2013 New search has been performed An update search was conducted in October 2012,
which resulted in 42 studies being added to awaiting
classiﬁcation. Upon close inspection of these studies,
none of them were included in this update. Thus, the
conclusion of this review remains unchanged
H I S T O R Y
Protocol ﬁrst published: Issue 1, 2010
Review ﬁrst published: Issue 3, 2010
Date Event Description
17 October 2012 Amended Update search of Cochrane Schizophrenia Group’s Trial Register (see Search methods for identiﬁcation
of studies),42 studies added to awaiting classification.
17 March 2010 Amended Previously combined studies split into separated studies and included in Excluded Studies section
17 March 2010 Amended Amendment of outcomes to be included in summary of ﬁndings table
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S O U R C E S O F S U P P O R T
Internal sources
• University of Nottingham, UK.
External sources
• National Institute for Health Research (CLAHRC), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Subsequent to the publication of the protocol we identiﬁed that our search strategy may have excluded some relevant studies, so we
added the words ’advice’ and ’monitor’ in the title of references section and added *advice* and *monitor* to the interventions of study
ﬁeld.
The original search phrase: [(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or *Smok* or *sex*
or *medical* or *dental* or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* in title of REFERENCES) AND
(*education* OR *health promot* OR *preventi* OR *motivate* in interventions of STUDY)] yielded 2326 references whilst the new
search phrase :[(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or *Smok* or *sex* or *medical*
or *dental* or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* or *advice* or *monitor* in title of REFERENCES)
AND (*education* OR *health promot* OR *preventi* OR *motivate* or *advice* or *monitor* in interventions of STUDY)] yielded
2383 references.
We have altered the text of the objectives to reﬂect the title of the review and outcomes of interest more accurately.
We have also corrected a typo in the outcomes where Quality of Life/Satisfaction should have readQuality of life or general functioning.
We also created a new outcome - Satisfaction with care.
32Physical health care monitoring for people with serious mental illness (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Health Status; ∗Quality of Life; Disease Progression; Mental Disorders [∗complications]
MeSH check words
Humans
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